---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Limitations of current therapies"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Limitations of current therapies. Topics: Resmetirom: histologic nonresponse, 52-week data, and absence of stopping rules (EASL-EASD-EASO); Semaglutide: histologic nonresponse at week 72 in ESSENCE and absence of predictors of response (AASLD); No FDA-approved noninvasive test for selection or monitoring (AASLD); Unverified clinical benefit of accelerated approvals, untested combinations, and no therapy for MASH cirrhosis (EASL-EASD-EASO research needs); 5 further topics. 10 evidence topics quoted from 18 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/limitations-of-current-therapies"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Limitations of current therapies

<a id="heading-2.2.2.1.7"></a>

## 2.2.2.1.7 Limitations of Current Therapies

<a id="topic-2.2.2.1.7-1"></a>

### Summary

Resmetirom and semaglutide 2.4 mg are approved for noncirrhotic MASH with moderate to advanced liver fibrosis, both under accelerated approval based on improvement of MASH and fibrosis. In the MAESTRO-NASH primary analysis population of 966 patients, NASH resolution with no worsening of fibrosis occurred in 25.9% (resmetirom 80 mg) and 29.9% (100 mg) compared with 9.7% (placebo), and fibrosis improvement by at least one stage in 24.2% and 25.9% compared with 14.2%. The EASL guideline states that evidence is limited to 52-week histological data, that about 70-80 % of participants did not respond according to histological criteria, and that there is no evidence to guide when to stop treatment. In the ESSENCE interim analysis of the first 800 patients at week 72, resolution of steatohepatitis occurred in 62.9% with semaglutide and 34.3% with placebo, and reduction in fibrosis in 36.8% and 22.4%; the AASLD semaglutide update states that 37.1% of treated participants did not resolve MASH and 63.2% did not have a reduction in fibrosis, and that available data do not identify predictors of response. No FDA-approved noninvasive test diagnoses MASH with F2 to F3 or monitors response to pharmacotherapy. Resmetirom and semaglutide have not been studied in combination or compared. Among 6837 resmetirom initiators, 37.2% had a recorded incretin prescription. The EASL guideline states that agents receiving accelerated approval must demonstrate beneficial effects on clinical outcomes and that no MASH-targeted pharmacotherapy can currently be recommended at the cirrhotic stage.

Other options have limits. Few patients (≤ 10%) achieve effective weight loss with structured interventions at 1 year, and fewer than half of these maintain it at 5 years; in one cohort, 88 of 293 participants (30%) lost 5% or more of their weight at week 52. Pioglitazone and vitamin E are not FDA approved for MASH, the EASL guideline does not recommend either as a MASH-targeted therapy, and in a 96-week trial in 247 adults without diabetes neither was associated with improvement in fibrosis scores; pioglitazone was associated with a mean weight gain of 4.7 kg at week 96, and its label states that thiazolidinediones cause or exacerbate congestive heart failure in some patients. The EASL guideline finds insufficient evidence to recommend SGLT2 inhibitors or metformin as MASH-targeted therapies. Metabolic surgery is not indicated solely for treatment of MASH, advanced fibrosis persisted in 47% of individuals in one post-surgery biopsy study, and in a cohort of 650 surgical patients with fibrotic NASH, 4 (0.6%) died from surgical complications within the first year.

Access and persistence are also limited. A diagnosis rate of ~10% (range 3.3% to 14.3%) of the treatment-eligible population has been estimated. In one cohort, 129 of 137 patients prescribed resmetirom (94.2%) required prior authorization, 33 (24.1%) prior authorization denials required appeal, and resmetirom was dispensed on average 22.7 days after prescription; in another cohort, 13 patients (16%) discontinued resmetirom after an average of 25.5 days, 11 because of adverse events. In company market research with 100 US MASH treaters, 85% of specialists described the greatest unmet needs as lack of effective, liver-directed therapies.

Source: [Madrigal Pharmaceuticals REZDIFFRA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217785s006lbl.pdf); [Novo Nordisk WEGOVY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf); [Harrison et al. (2024)](https://www.nejm.org/doi/full/10.1056/NEJMoa2309000); [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext); [Sanyal et al. (2025)](https://www.nejm.org/doi/full/10.1056/NEJMoa2413258); [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated); [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated); [Papadimopoulos et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43039875/); [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/); [Vilar-Gomez et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25865049/); [Sanyal et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2928471/); [Takeda Pharmaceuticals ACTOS prescribing information (2017)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021073s049lbl.pdf); [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690184/); [Aminian et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8587225/); [Fishman et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480167/); [Shuaibi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12271776/); [Ravela et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11970881/); [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-2.2.2.1.7-2"></a>

### Resmetirom: histologic nonresponse, 52-week data, and absence of stopping rules (EASL-EASD-EASO)

> “Importantly, evidence is currently limited to 52-week histological outcome data. This raises uncertainty as to whether responses will be sustained in the long-term. Similarly, there is currently no evidence to provide confident guidance on when to stop treatment, particularly considering that about 70-80 % of participants did not respond to treatment according to histological criteria.”
> “For individuals with MASLD undergoing therapy with resmetirom, data on sustainability of histological benefits, individual prediction of response, liver-related outcomes and long-term safety are not currently available (LoE 5, strong consensus).”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.7-3"></a>

### Semaglutide: histologic nonresponse at week 72 in ESSENCE and absence of predictors of response (AASLD)

> “In the ESSENCE trial, 37.1% of participants treated with semaglutide did not resolve MASH, and 63.2% did not have a reduction in fibrosis without worsening of steatohepatitis by week 72. At the current time, we do not have data from the ESSENCE trial to reliably identify patients who are unlikely to resolve MASH or regress liver fibrosis with 72 weeks of semaglutide treatment.”
> “Publicly available data from the ESSENCE trial do not allow an assessment of blood tests and other NITs that predict response to treatment (and this is generally an unmet need in clinical trials of MASH pharmacotherapy).”

Source: [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated)

<a id="topic-2.2.2.1.7-4"></a>

### No FDA-approved noninvasive test for selection or monitoring (AASLD)

> “There are no FDA-approved noninvasive tests to diagnose MASH with F2-F3 or to monitor response to pharmacotherapy.”
> “Since the FDA-approved resmetirom prescribing information”
> “does not include implementable guidance for practicing clinicians about whom to treat and how to monitor for response and safety”

Source: [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated)

<a id="topic-2.2.2.1.7-5"></a>

### Unverified clinical benefit of accelerated approvals, untested combinations, and no therapy for MASH cirrhosis (EASL-EASD-EASO research needs)

> “With the registration of resmetirom and potentially other agents in the future, it is important to define non-response and stopping rules as well as to ascertain their long-term metabolic (e.g. bone density, endocrine functions), cardiovascular and oncological (e.g. extrahepatic malignancy) safety. The potential additive or synergistic effects of combining drugs intended to treat MASH and/or cardiometabolic comorbidities needs to be prospectively assessed. All pharmacological agents receiving accelerated approval for the treatment of MASH must demonstrate beneficial effects on clinical outcomes (i.e. mortality, decompensation, liver transplantation, HCC) in the extended period of phase III clinical trials and real-world studies. In addition, it is important to develop effective pharmacological treatments for individuals with MASH-related cirrhosis.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

<a id="topic-2.2.2.1.7-6"></a>

### Combined resmetirom and semaglutide: not studied (AASLD and real-world US cohort)

> “However, semaglutide and resmetirom have not been studied as a combination therapy for MASH, nor have they been compared for relative efficacy.”

Source: [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated)

> “Resmetirom and semaglutide 2.4 mg are approved for metabolic dysfunction-associated steatohepatitis but have not been tested together.”
> “Because more than one-third of resmetirom initiators had a recorded incretin prescription, mostly before initiation, trials of combined treatment are needed.”

Source: [Papadimopoulos et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43039875/)

<a id="topic-2.2.2.1.7-7"></a>

### Diagnosis rate of the treatment-eligible US population (Madrigal-funded population calculator)

> “Published analyses suggest a diagnosis rate of ~ 10% (range 3.3–14.3%) and ~ 16% year-over-year growth in the treatment-eligible population.”
> “Estimation of the treatment-eligible population for resmetirom depends importantly on NASH diagnosis rates, which are predicted to be < 15% in the 3 years after drug approval.”

Source: [Fishman et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480167/)

<a id="topic-2.2.2.1.7-8"></a>

### Real-world resmetirom access: prior authorization, denials, and dispensing delays at a US tertiary center

> “Among the 137 patients prescribed resmetirom, 129 patients (94.2%) required insurance prior authorization. A total of 33 (24.1%) insurance prior authorization denials were seen, which required an appeal for insurance approval.”
> “Appeals were denied due to unmet biopsy requirements, expired noninvasive fibrosis testing, or complete plan exclusions. On average, resmetirom was dispensed 22.7 days after being prescribed, with a delay of 12.5 days after insurance approval.”
> “Despite insurance approvals, access challenges persisted, with 5 patients discontinuing treatment prematurely due to cost concerns when nonprofit foundation grants were unavailable or logistical issues with specialty pharmacy dispensing.”

Source: [Shuaibi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12271776/)

<a id="topic-2.2.2.1.7-9"></a>

### Real-world resmetirom discontinuation in a US hepatology prescription pathway

> “Thirteen patients (16%) discontinued resmetirom after an average of 25.5 days (range: 2–68 d), with 11 patients discontinuing due to adverse events.”
> “One in 6 patients discontinued resmetirom, primarily due to side effects.”

Source: [Ravela et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11970881/)

<a id="topic-2.2.2.1.7-10"></a>

### Unmet need reported by US MASH treaters (Inventiva market research)

> “Despite the emergence of new treatment options, US HCPs feel that unmet need in MASH remains significant”
> “Without a prompt 85% of specialists in the US described the greatest unmet needs as lack of effective, liver directed therapies”
> “Global Primary Quant Patient Journey Market Research Jul. - Sep. ’25 (n=100). All HCPs were US MASH treaters”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
